apceth Biopharma Appoints Dusan Kosijer as Chief Financial Officer

apceth logo

Munich, Germany, May 31, 2017 / B3C newswire / -- apceth Biopharma GmbH, a cell therapy company with a proprietary portfolio of genetically modified mesenchymal stem cell therapeutics for the treatment of inflammatory diseases and cancer, and a successful Contract Development and Manufacturing Organisation (CDMO) for cell and gene therapy products, announced today the appointment of Mr Dusan Kosijer as new Chief Financial Officer, effective immediately.

Mr Kosijer has joined apceth's team already in October 2016, taking over the responsibility for the company's finance strategy and operations, and also the leadership of apceth's accountant and purchasing team. Mr Kosijer is Certified Management Accountant by training and brings with him 14 years of outstanding experience at leading positions in corporate finance and pharmaceutical contract service business. He joined apceth from his previous position as CFO at Accovion GmbH, one of the leading independent European Clinical Research Organisations.

In his new role as a member of the senior management, Mr Kosijer's key impact on apceth's effective business and executive strategy will intensify further.

"I am very pleased to welcome Dusan to apceth's executive management team. With his longstanding background as a finance executive in the pharmaceutical contract services sector, he will play a major role in further strengthening our successful track record as one of the leading CDMOs for complex cell and gene therapy products," said Dr Christine Guenther, apceth's CEO, and added: "Moreover, Dusan's experience will strongly promote our dynamic innovative strategy behind apceth's unique proprietary pipeline of genetically modified stem cell therapies."

"I am excited and honoured to be able to contribute to the company that operates successfully for almost 10 years in the fast-moving field of cell and gene therapy,” said Mr Kosijer. “We will continue to be relentless in our efforts to be the best and the most reliable CDMO partner for the growing number of our renowned international clients. In parallel, apceth's pipeline has recently entered a very thrilling phase, encouraging us to accelerate further the development of our first-in-class, first-in-man cell-based gene therapies."

Dusan Kosijer

Caption: Dusan Kosijer, CFO, apceth Biopharma

About apceth Biopharma GmbH
apceth Biopharma is a pioneering biopharmaceutical company with a pipeline of cell-based gene therapeutics for the treatment of major chronic diseases (chronic lung disease, metabolic and autoimmune diseases) and solid cancer. The company's proprietary platform technology is based on state-of-the-art genetic engineering of mesenchymal stem cells. apceth Biopharma is also a successful Contract Development and Manufacturing Organization for complex cell and gene therapy products with a high international reputation. Based in Munich (Germany) in the heart of Europe, apceth Biopharma provides its proven expertise and state-of-the-art GMP facilities to the clients from around the world. apceth Biopharma was founded as apceth GmbH & Co. KG in 2007. The company is privately owned by its founders and private investors (Santo Holding GmbH and FCP Biotech Holding GmbH).


apceth Biopharma GmbH
Dr Christine Guenther, CEO
Max-Lebsche-Platz 30
81377 Munich
+49 (0)89 7009608 0
This email address is being protected from spambots. You need JavaScript enabled to view it.   

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.